Novel Therapies for the Treatment of Acute Myeloid Leukemia

December 15th, 2020 - December 15th, 2021


This session on Acute Myelogenous Leukemia will discuss the prognostic significance and therapeutic implications of genetic testing. Novel oral medications for inhibition of FLT3, IDH1, IDH2, and BCL2 are reviewed, along with strategies for managing associated toxicities.

This activity was originally presented at an APP Oncology Summit in 2020.  The APP Oncology Summit is a two-day conference designed to provide advanced practice providers (APPs) with the latest evidenced-based strategies to optimize care and outcomes for patients with cancer. This conference is planned with and for advanced practice providers (NPs, PAs, pharmacists, and nurse specialists) and is a collaborative effort of oncology clinicians from multiple organizations in each community. APP Oncology Summit offers a unique opportunity for APPs from various healthcare teams in the community to collaborate, learn from each other and national faculty, and share best practices on a range of issues related to the care of cancer patients. 

Target Audience
This activity has been designed to meet the educational needs of oncology nurse practitioners (NPs), physician assistants (PAs), nurse specialists, and other health care providers involved in the management of oncology patients. 

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Review the prognostic and treatment significance of genetic aberrations in AML, including methods for detection and timing of testing

  • Describe the mechanism of action and clinical trial data for currently approved novel therapies for the treatment of AML including FLT3, IDH1, IDH2, and BCL-2 inhibitors

  • Implement strategies for the management of side effects associated with novel therapies in AML

Activity Launch Date - 12/15/2020
Expiration Date - 12/15/2021

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Statement of Independence
Horizon CME educational activities are developed and conducted in accordance with the ACCME's Essential Areas and Policies.  It is the mission of Horizon CME to develop and present educational activities that are timely, fair balanced, scientifically rigorous, and that serve to improve patient outcomes.  To that end, we welcome comments about how to better serve your needs.

Copyright Information
© 2020 - All rights reserved. This CME-certified program is held as copyrighted by Horizon CME. Through this notice, Horizon CME grants permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owners.